Cutaneous T-cell lymphoma (CTCL) is the most common type of cutaneous lymphoma, and typically presents with red, scaly patches or plaques on the skin. The global market for CTCL is estimated to reach $1.6 Billion by 2025 (Diligent Market Research, 2017). CTCL often mimics eczema, psoriasis, or other chronic dermatitis, and because of this it’s common that the diagnosis of CTCL is delayed, sometimes by years or decades. Approximately 15% of CTCL patients will develop a life-threatening systemic form of CTCL know as Sezary Syndrome with a mortality rate of 80% within 4 years. CTCL is a designated by the FDA “orphan” status and is a condition with unmet needs.
As a group, CTCL is a rare family of diseases. While the number of new cases diagnosed each year is relatively low (about 3,000), it is estimated that, since patients have a very long survival, there may be as many as 30,000 patients living with cutaneous lymphoma in the United States and Canada. MF is more common in men compared to women, in blacks compared to whites, and in patients older than 50 years of age compared to younger people. Due to the difficulty of diagnosing the disease in its early stages, the slow course of MF, and the lack of an accurate reporting system, these numbers are probably low estimates. Breakthrough Therapies